Abstract
BackgroundRespiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infections in infants. There are still no vaccines or specific antiviral therapies against RSV, mainly due to the inadequate understanding of RSV pathogenesis. Recent data suggest a role for gut microbiota community structure in determining RSV disease severity. Our objective was to determine the gut microbial profile associated with severe RSV patients, which could be used to help identify at-risk patients and develop therapeutically protective microbial assemblages that may stimulate immuno-protection.ResultsWe enrolled 95 infants from Le Bonheur during the 2014 to 2016 RSV season. Of these, 37 were well-babies and 58 were hospitalized with RSV. Of the RSV infected babies, 53 remained in the pediatric ward (moderate) and 5 were moved to the pediatric intensive care unit at a later date (severe). Stool samples were collected within 72 h of admission; and the composition of gut microbiota was evaluated via 16S sequencing of fecal DNA. There was a significant enrichment in S24_7, Clostridiales, Odoribacteraceae, Lactobacillaceae, and Actinomyces in RSV (moderate and severe) vs. controls. Patients with severe RSV disease had slightly lower alpha diversity (richness and evenness of the bacterial community) of the gut microbiota compared to patients with moderate RSV and healthy controls. Beta diversity (overall microbial composition) was significantly different between all RSV patients (moderate and severe) compared to controls and had significant microbial composition separating all three groups (control, moderate RSV, and severe RSV).ConclusionsCollectively, these data demonstrate that a unique gut microbial profile is associated with RSV disease and with severe RSV disease with admission to the pediatric intensive care unit. More mechanistic experiments are needed to determine whether the differences observed in gut microbiota are the cause or consequences of severe RSV disease.
Highlights
Respiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infections in infants
Respiratory syncytial virus (RSV) is a ubiquitous respiratory virus infecting the majority of the human population by 1 year of age [1]
Because there are a vast number of microbes residing in the gut, there is no shortage of microorganism-associated molecular patterns (MAMPs) as well as pathogen-associated molecular patterns (PAMPs) that can initiate in the gut and alter immune functions in the lung [24]
Summary
Respiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infections in infants. Our objective was to determine the gut microbial profile associated with severe RSV patients, which could be used to help identify at-risk patients and develop therapeutically protective microbial assemblages that may stimulate immuno-protection. Respiratory syncytial virus (RSV) is a ubiquitous respiratory virus infecting the majority of the human population by 1 year of age [1]. In the U.S alone, RSV causes 85,000 to 144,000 hospitalizations [4], 14,000 deaths [2], and ~ $2.6 billion in medical care costs each year [5]. In view of the fact that RSV is a “significant unmet medical need” [6] with no known vaccine, there is a necessity to find therapeutic approaches to prevent and treat severe RSV infections
Full Text
Topics from this Paper
Severe RSV Disease
Severe RSV
RSV Disease
Respiratory Syncytial Virus Disease Severity
Respiratory Tract Infections In Infants
+ Show 5 more
Create a personalized feed of these topics
Get StartedTalk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
The Journal of Pediatrics
Mar 1, 2015
European Journal of Epidemiology
Jun 14, 2008
Expert Opinion on Therapeutic Patents
Mar 1, 2002
Canadian Journal of Infectious Diseases and Medical Microbiology
Nov 30, 2020
Immunity
Feb 1, 2017
Sri Lanka Journal of Child Health
Sep 5, 2023
The Journal of allergy and clinical immunology
Sep 1, 2022
Pediatric Pulmonology
Jan 1, 1999
New England Journal of Medicine
Jul 30, 2020
Paediatrics and Child Health
Sep 1, 2007
Indoor Air
Oct 23, 2020
International Journal of Women's Health
May 1, 2011
PLOS Pathogens
Mar 6, 2018
BMC Microbiology
BMC Microbiology
Nov 27, 2023
BMC Microbiology
Nov 27, 2023
BMC Microbiology
Nov 24, 2023
BMC Microbiology
Nov 24, 2023
BMC Microbiology
Nov 22, 2023
BMC Microbiology
Nov 22, 2023
BMC Microbiology
Nov 20, 2023
BMC Microbiology
Nov 18, 2023
BMC Microbiology
Nov 18, 2023
BMC Microbiology
Nov 18, 2023